Meeting
2023 ASCO Genitourinary Cancers Symposium
Intravesical gemcitabine and docetaxel in the treatment of BCG-naïve non–muscle invasive urothelial carcinoma of the bladder: Updates from a phase 2 trial.
Authors
Sunil H. Patel
James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, MD
Sunil H. Patel , Andrew Gabrielson , Connie Collins , Nirmish Singla , Trinity Bivalacqua , Noah M. Hahn , Max R. Kates
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Prostate Cancer and Urothelial Carcinoma
Track
Urothelial Carcinoma,Prostate Cancer - Advanced
Sub Track
Therapeutics
Citation
J Clin Oncol 41, 2023 (suppl 6; abstr 507)
DOI
10.1200/JCO.2023.41.6_suppl.507
Abstract #
507
Poster Bd #
K11
Abstract Disclosures
Similar Posters
Poster
2019 Genitourinary Cancers Symposium
Sequential intravesical gemcitabine and docetaxel in the treatment of BCG-naive patients with non-muscle invasive bladder cancer.
First Author: Lewis Thomas
Poster
2023 ASCO Annual Meeting
Phase 2 trial of intravesical cabazitaxel, gemcitabine, and cisplatin (CGC) for the treatment of non-muscle invasive BCG unresponsive urothelial carcinoma of the bladder.
First Author: Guarionex Joel DeCastro
Poster
2023 ASCO Genitourinary Cancers Symposium
A phase II trial of intravesical chemoimmunotherapy with gemcitabine and bacillus Calmette-Guérin (BCG) for patients with BCG-exposed, high-grade, non-muscle–invasive bladder cancer.
First Author: Christopher Gaffney
Poster
2022 ASCO Genitourinary Cancers Symposium
Long-term follow-up of intravesical gemcitabine and docetaxel as rescue therapy for nonmuscle-invasive bladder cancer.
First Author: Phani T. Chevuru